1. Home
  2. BEAM

BEAM

Beam Therapeutics Inc.

Logo Beam Therapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-23-2024 12:30pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Founded: 2017 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 2.0B IPO Year: 2020
Target Price: $41.56 AVG Volume (30 days): 1.6M
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.72 EPS Growth: N/A
52 Week Low/High: $16.95 - $49.50 Next Earning Date: 05-08-2024
Revenue: $377,709,000 Revenue Growth: 520.01%
Revenue Growth (this year): -82.87% Revenue Growth (next year): 1.39%

Share on Social Networks:

Stock Insider Trading Activity of Beam Therapeutics Inc. (BEAM)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Simon Amy BEAM Chief Medical Officer Apr 1 '24 Sell $32.13 7,157 $229,954.41 86,590 SEC Form 4
Simon Amy BEAM Chief Medical Officer Apr 1 '24 Sell $30.54 16,530 $504,851.00 70,060 SEC Form 4
Evans John M. BEAM CEO Apr 1 '24 Sell $32.13 18,102 $581,617.26 1,058,343 SEC Form 4
FMR LLC BEAM Feb 13 '24 Sell $31.34 45,677 $1,431,517.18 1,235,511 SEC Form 4
FMR LLC BEAM Feb 13 '24 Sell $30.51 854,323 $26,065,394.73 1,281,188 SEC Form 4
FMR LLC BEAM Feb 13 '24 Sell $30.93 1,155 $35,724.15 2,771,913 SEC Form 4
FMR LLC BEAM Feb 13 '24 Sell $30.28 410 $12,414.80 2,773,068 SEC Form 4